Do Amiodaron or a „shock-only“ ICD reduce the all-cause mortality compared to placebo* in patients with ischemic or non-ischemic NYHA II or III CHF and EF < 35%
Do Amiodaron or a „shock-only“ ICD reduce the all-cause mortality compared to placebo* in patients with ischemic or non-ischemic NYHA II or III CHF and EF < 35%
Do Amiodaron or a „shock-only“ ICD reduce the all-cause mortality compared to placebo* in patients with ischemic or non-ischemic NYHA II or III CHF and EF < 35%